Mailian Medical raises $14M for at-home BCI rehab
Zhejiang Mailian Medical Technology has closed a 100 million yuan ($14.1 million) Series B round to expand its at-home neuro-rehabilitation platform. The Hangzhou-based startup did not disclose investors.
According to the company, its technology aims to enable rehabilitation by interpreting neural signals without invasive procedures. The approach could offer an alternative to surgical BCI systems, though details about its mechanism or target conditions were not provided.
The funding follows recent activity in China’s BCI sector, including Sequoia China’s multimillion-dollar angel round in Tianfukang Medical Technology earlier this month. While investor enthusiasm appears to be rising, it remains unclear whether non-invasive BCI systems will achieve scalable adoption in home settings.
No details were shared about Mailian’s commercial progress, including user numbers, revenue, or regulatory status. The startup’s path to market may depend on whether it can align with existing outpatient models or secure clinical partnerships.
Sources: chinatechnews.com
“The round may signal growing investor interest in non-invasive BCI as a potential home-health category, though commercial viability remains unproven.”
Read the original reporting
The outlets below did the original reporting.
Related briefs
- Startup Battlefield 200 finalists compete at Disrupt 2026
- Allara raises $30M to scale AI-augmented women’s health care
- Founders rethink venture capital fit amid funding shifts
- Super apps may rise where mobile meets weak banking, says VC
- Fundamentum Frontier Advisors secures ₹3,000 cr in first close for AI, deeptech fund
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.